# Blossom Biosciences (博胜药业)
Blossom Biosciences (博胜药业) is a biopharmaceutical company launched on June 16, 2021, co-founded and incubated by Hansoh Pharmaceutical Group Company Limited (3692.HK) and Cormorant Asset Management to in-license and develop what the founders described as potentially transformative medicines for patients in greater China.[1](https://www.hansoh.cn/en/news/news-detail-513700.htm) The company closed a USD 72 million Series A financing at launch, co-led by its two parents, and its Hong Kong-registered legal entity, Blossom Bioscience Limited (博胜药业有限公司), remains recorded as Live; the only later public company item found is VCBeat's headline reporting that Blossom filed an IPO prospectus, which no other source corroborates.[1](https://www.hansoh.cn/en/news/news-detail-513700.htm) • [2](https://hongkongcompanysearch.com/company/1FTWZZt62Zb0I6u302C3kD7m3.html) • [3](https://www.vcbeathealth.com/article/25114)
| Key fact | Detail |
|---|---|
| Launched | June 16, 2021, announced from Boston and Shanghai[1](https://www.hansoh.cn/en/news/news-detail-513700.htm) • [4](https://www.newswire.com/news/cormorant-asset-management-and-hansoh-pharmaceutical-group-company-21417480) |
| Legal entity | Blossom Bioscience Limited (博胜药业有限公司), incorporated in Hong Kong on May 10, 2021, company number 3046781[2](https://hongkongcompanysearch.com/company/1FTWZZt62Zb0I6u302C3kD7m3.html) |
| Founders/incubators | Hansoh Pharmaceutical Group (3692.HK) and Cormorant Asset Management[1](https://www.hansoh.cn/en/news/news-detail-513700.htm) |
| Interim CEO | Andrew Phillips, Ph.D., Managing Director at Cormorant, previously CEO of C4 Therapeutics (Nasdaq: CCCC)[1](https://www.hansoh.cn/en/news/news-detail-513700.htm) |
| Disclosed funding | USD 72 million Series A, June 2021, co-led by Hansoh and Cormorant[1](https://www.hansoh.cn/en/news/news-detail-513700.htm) • [5](https://finance.sina.com.cn/tech/2021-06-17/doc-ikqciyzk0082054.shtml) |
| Business model | In-licensing assets via Cormorant's global biotech network, with Hansoh providing pre-clinical, clinical, and commercialization support in greater China[1](https://www.hansoh.cn/en/news/news-detail-513700.htm) |
| Status as last recorded | HK registration Live; the only public company news found between June 2021 and September 2026 is VCBeat's uncorroborated IPO-prospectus headline[2](https://hongkongcompanysearch.com/company/1FTWZZt62Zb0I6u302C3kD7m3.html) • [3](https://www.vcbeathealth.com/article/25114) |
## History and founding
The company was announced on June 16, 2021 in a release datelined Boston and Shanghai, framed as a launch by two established life-sciences backers rather than a single-founder startup.[4](https://www.newswire.com/news/cormorant-asset-management-and-hansoh-pharmaceutical-group-company-21417480) Hansoh Pharmaceutical Group, the Hong Kong-listed pharmaceutical group whose main operating entity 豪森药业 was founded in 1995 and reported more than 1,600 R&D professionals as of December 2020, incubated the venture alongside Cormorant Asset Management, a life-sciences investment firm founded in 2013 with over USD 3 billion in assets under management as of June 2021.[1](https://www.hansoh.cn/en/news/news-detail-513700.htm) • [6](https://cn.hspharm.com/news/news-detail-9756.htm)
At launch, Andrew Phillips, Ph.D., a Managing Director at [Cormorant](https://www.edgepedia.org/cormorant) and previously Chief Executive Officer of C4 Therapeutics, Inc. (Nasdaq: CCCC), was appointed interim Chief Executive Officer.[1](https://www.hansoh.cn/en/news/news-detail-513700.htm) The executives behind the venture on the two parents' side were Hansoh executive director Sun Yuan (孙远), who described Cormorant as a partner whose resources would help Blossom develop breakthrough therapies in China, and Cormorant founder and CEO Chen Bihua (陈碧华).[6](https://cn.hspharm.com/news/news-detail-9756.htm) • [5](https://finance.sina.com.cn/tech/2021-06-17/doc-ikqciyzk0082054.shtml)
## Business model
Blossom was set up as a licensing-led development company rather than a discovery-stage biotech. Under an agreement signed at launch, Hansoh provides pre-clinical, clinical, and commercialization support to accelerate development and launch of Blossom's pipeline in greater China, while Cormorant leverages its global biotech network and portfolio companies to in-license assets to the company.[1](https://www.hansoh.cn/en/news/news-detail-513700.htm) Trade outlet DrugTimes reported the same arrangement, noting that Cormorant committed to support Blossom in introducing innovative products through its global biopharma resources and portfolio companies.[7](https://www.drugtimes.cn/2021/06/16/hansenzhiyaoxieshouyuyingziguanchengliboshengyaoye/)
Interim CEO Andrew Phillips said at launch that in the near future Blossom hoped to rely on its operating model and execution efficiency to introduce a series of pipeline products.[5](https://finance.sina.com.cn/tech/2021-06-17/doc-ikqciyzk0082054.shtml)
## Funding
The company's only disclosed financing is the USD 72 million Series A that closed at launch, co-led by Hansoh and Cormorant, which the company said would fund its effort to bring potentially transformative medicines to patients in greater China.[1](https://www.hansoh.cn/en/news/news-detail-513700.htm) The round was independently corroborated on June 17, 2021 by Sina Tech, citing the Beijing dateline of 猎云网, which reported the same amount and the same two co-lead investors.[5](https://finance.sina.com.cn/tech/2021-06-17/doc-ikqciyzk0082054.shtml)
For comparison, a comparable peer, Hangzhou antibody-drug conjugate developer Bliss Biopharma (百力司康), raised RMB 435 million in 2021 in a round co-invested by GL Ventures, Cormorant, VMS, and Heda Biopharma Fund; Cormorant appears in that cap table as well, and Bliss's five pre-IPO rounds totaled about RMB 874 million.[8](https://www.mrjjxw.com/articles/2025-07-12/3942168.html)
## Name and base of operations
The founders' official Chinese and English releases print the name as Blossom Biosciences (博胜药业).[1](https://www.hansoh.cn/en/news/news-detail-513700.htm) • [6](https://cn.hspharm.com/news/news-detail-9756.htm) The Newswire distribution and the Hong Kong registry's registered English name use the singular form Blossom Bioscience Limited.[4](https://www.newswire.com/news/cormorant-asset-management-and-hansoh-pharmaceutical-group-company-21417480) • [2](https://hongkongcompanysearch.com/company/1FTWZZt62Zb0I6u302C3kD7m3.html) VCBeat's English coverage renders the company as "Bosheng Pharma" and Cormorant as "Osprey Asset Management".[3](https://www.vcbeathealth.com/article/25114) On geography, the launch announcement is datelined Boston and Shanghai and the identified legal entity is Hong Kong-incorporated, while a Chinese press report was datelined Beijing.[5](https://finance.sina.com.cn/tech/2021-06-17/doc-ikqciyzk0082054.shtml) • [4](https://www.newswire.com/news/cormorant-asset-management-and-hansoh-pharmaceutical-group-company-21417480) • [2](https://hongkongcompanysearch.com/company/1FTWZZt62Zb0I6u302C3kD7m3.html)
## Recent developments
The public record after June 2021 is thin. The Hong Kong entity Blossom Bioscience Limited was incorporated on May 10, 2021, before the launch announcement, as a [private company limited by shares](https://www.edgepedia.org/private-company-limited-by-shares), has had no name changes since incorporation, and is recorded as Live.[2](https://hongkongcompanysearch.com/company/1FTWZZt62Zb0I6u302C3kD7m3.html) No new funding round, partnership, licensing deal, clinical-trial filing, or corporate announcement by or about the company was found between the June 2021 launch and September 2026 apart from VCBeat's IPO-prospectus headline. VCBeat's article headline states that Blossom Biosciences filed an IPO prospectus following its Series A, but no other source mentions such a filing and it remains uncorroborated.[3](https://www.vcbeathealth.com/article/25114)
## References
1. [Cormorant Asset Management and Hansoh Pharmaceutical Group Company Limited Launches Blossom Biosciences (Hansoh official English press release)](https://www.hansoh.cn/en/news/news-detail-513700.htm)
2. [博胜药业有限公司 (Blossom Bioscience Limited) Hong Kong registry record](https://hongkongcompanysearch.com/company/1FTWZZt62Zb0I6u302C3kD7m3.html)
3. [Blossom Biosciences Files IPO Prospectus Following $72M Series A Backed by Hansoh Pharma and Cormorant Asset Management (VCBeat)](https://www.vcbeathealth.com/article/25114)
4. [Cormorant Asset Management and Hansoh Pharmaceutical Group Company Limited Launch Blossom Bioscience (Newswire)](https://www.newswire.com/news/cormorant-asset-management-and-hansoh-pharmaceutical-group-company-21417480)
5. [博胜药业完成7200万美元A轮融资，翰森制药和鱼鹰资管共同领投 (Sina Tech / 猎云网, 2021-06-17)](https://finance.sina.com.cn/tech/2021-06-17/doc-ikqciyzk0082054.shtml)
6. [翰森制药携手鱼鹰资管成立博胜药业 (Hansoh official Chinese-language press release)](https://cn.hspharm.com/news/news-detail-9756.htm)
7. [翰森制药携手鱼鹰资管成立博胜药业 (药时代 DrugTimes)](https://www.drugtimes.cn/2021/06/16/hansenzhiyaoxieshouyuyingziguanchengliboshengyaoye/)
8. [2名中国顶尖大学毕业、赴美深造的女博士创业开公司… (每日经济新闻, July 2025)](https://www.mrjjxw.com/articles/2025-07-12/3942168.html)
---
*Topic: Encyclopedia › Society and history › Economics and business › Business and work › Business and work overview › Companies and corporations › Venture-backed startups and growth companies › Health, biotech, and medtech startups › Small-molecule and chemical drug developers › Cardiovascular and metabolic drug developers*
*Initially written Sep 17, 2026 · Reviewed: Sep 20, 2026 · Edited: Sep 20, 2026; Oct 15, 2026 · Last review: Sep 20, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license